CytomX Therapeutics (CTMX) Shares Outstanding (2014 - 2026)

CytomX Therapeutics (CTMX) has 13 years of Shares Outstanding (Entity) data on file, last reported at $177.3 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 119.88% year-over-year to $177.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $177.3 million (up 119.88% YoY) and the FY2025 annual result came in at $137.9 million, up 72.2% from the prior year.
• Shares Outstanding (Entity) improved to $177.3 million in Q1 2026, from $137.9 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $177.3 million in Q1 2026 to a low of $65.4 million in Q1 2022.
• A 5-year average of $90.0 million and a median of $68.1 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) rose 0.61% — and 2026, when it surged 119.88%.
• Tracing CTMX's Shares Outstanding (Entity) over 5 years: stood at $66.2 million in 2022, then advanced by 1.63% to $67.3 million in 2023, then advanced by 19.0% to $80.1 million in 2024, then soared by 72.2% to $137.9 million in 2025, then rose by 28.52% to $177.3 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $177.3 million (Q1 2026), $137.9 million (Q4 2025), and $169.4 million (Q3 2025), per Business Quant data.